You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameLevetiracetam
Accession NumberDB01202  (APRD01068)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionLevetiracetam is an anticonvulsant medication used to treat epilepsy. Levetiracetam may selectively prevent hypersynchronization of epileptiform burst firing and propagation of seizure activity. Levetiracetam binds to the synaptic vesicle protein SV2A, which is thought to be involved in the regulation of vesicle exocytosis. Although the molecular significance of levetiracetam binding to synaptic vesicle protein SV2A is not understood, levetiracetam and related analogs showed a rank order of affinity for SV2A which correlated with the potency of their antiseizure activity in audiogenic seizure-prone mice.
Structure
Thumb
Synonyms
Levetiracetam
Levetiracetame
Levetiracetamum
Levitiracetam
External Identifiers
  • UCB 22059
  • UCB L059
  • UCB-22059
  • UCB-L059
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Abbott-levetiracetamtablet750 mgoralAbbott Laboratories, Limited2014-05-302015-12-31Canada
Abbott-levetiracetamtablet250 mgoralAbbott Laboratories, Limited2014-05-302015-12-31Canada
Abbott-levetiracetamtablet500 mgoralAbbott Laboratories, Limited2014-05-302015-12-31Canada
Act Levetiracetamtablet250 mgoralActavis Pharma Company2005-12-07Not applicableCanada
Act Levetiracetamtablet500 mgoralActavis Pharma Company2005-12-07Not applicableCanada
Act Levetiracetamtablet750 mgoralActavis Pharma Company2005-12-07Not applicableCanada
Auro-levetiracetamtablet500 mgoralAuro Pharma Inc2012-03-15Not applicableCanada
Auro-levetiracetamtablet750 mgoralAuro Pharma Inc2012-02-14Not applicableCanada
Auro-levetiracetamtablet250 mgoralAuro Pharma Inc2012-02-14Not applicableCanada
Ava-levetiracetamtablet250 mgoralAvanstra Inc2011-10-112014-08-21Canada
Ava-levetiracetamtablet500 mgoralAvanstra Inc2011-10-112014-08-21Canada
Ava-levetiracetamtablet750 mgoralAvanstra Inc2011-10-112014-08-21Canada
Bio-levetiracetamtablet250 mgoralBiomed PharmaNot applicableNot applicableCanada
Bio-levetiracetamtablet500 mgoralBiomed PharmaNot applicableNot applicableCanada
Bio-levetiracetamtablet750 mgoralBiomed PharmaNot applicableNot applicableCanada
Dom-levetiracetamtablet750 mgoralDominion Pharmacal2008-04-16Not applicableCanada
Dom-levetiracetamtablet250 mgoralDominion Pharmacal2008-04-16Not applicableCanada
Dom-levetiracetamtablet500 mgoralDominion Pharmacal2008-04-16Not applicableCanada
Elepsia XRtablet, extended release1000 mg/1oralSun Pharma Advanced Research Company Limited2015-03-13Not applicableUs
Elepsia XRtablet, extended release1500 mg/1oralSun Pharma Advanced Research Company Limited2015-03-13Not applicableUs
Jamp-levetiracetamtablet250 mgoralJamp Pharma Corporation2013-04-29Not applicableCanada
Jamp-levetiracetamtablet500 mgoralJamp Pharma Corporation2013-04-29Not applicableCanada
Jamp-levetiracetamtablet750 mgoralJamp Pharma Corporation2013-04-29Not applicableCanada
Kepprasolution100 mg/mLoralUCB, Inc.2003-10-20Not applicableUs
Keppratablet, film coated500 mg/1oralSTAT Rx USA LLC2000-04-24Not applicableUs
Keppratablet, film coated500 mg/1oralPhysicians Total Care, Inc.2003-10-30Not applicableUs
Keppratablet, film coated1000 mg/1oralUCB, Inc.2000-04-24Not applicableUs
Keppratablet, film coated750 mg/1oralRx Pak Division Of Mc Kesson Corporation2014-05-16Not applicableUs
Keppratablet1000 mg/1oralUCB Farchim S.A.2000-04-242016-04-05Us
Keppratablet, film coated250 mg/1oralUCB, Inc.2000-04-24Not applicableUs
Keppratablet, film coated750 mg/1oralSTAT Rx USA LLC2000-04-24Not applicableUs
Keppratablet, film coated750 mg/1oralPhysicians Total Care, Inc.2005-04-15Not applicableUs
Keppratablet250 mgoralUcb Canada Inc2003-07-23Not applicableCanada
Keppratablet, film coated500 mg/1oralRx Pak Division Of Mc Kesson Corporation2014-05-16Not applicableUs
Keppratablet, film coated500 mg/1oralUCB, Inc.2000-04-24Not applicableUs
Keppratablet500 mg/1oralRebel Distributors Corp2000-04-24Not applicableUs
Kepprainjection, solution, concentrate100 mg/mLintravenousCardinal Health2006-07-31Not applicableUs
Keppratablet500 mgoralUcb Canada Inc2003-07-23Not applicableCanada
Keppratablet, film coated1000 mg/1oralRx Pak Division Of Mc Kesson Corporation2014-05-16Not applicableUs
Keppratablet, film coated750 mg/1oralUCB, Inc.2000-04-24Not applicableUs
Keppratablet, film coated500 mg/1oralPd Rx Pharmaceuticals, Inc.2000-04-24Not applicableUs
Keppratablet750 mg/1oralUCB Farchim S.A.2000-04-242016-04-05Us
Kepprainjection, solution, concentrate100 mg/mLintravenousUCB, Inc.2006-08-23Not applicableUs
Keppratablet, film coated750 mg/1oralREMEDYREPACK INC.2013-02-282016-04-05Us
Keppratablet750 mgoralUcb Canada Inc2003-07-23Not applicableCanada
Keppra XRtablet, film coated, extended release500 mg/1oralRx Pak Division Of Mc Kesson Corporation2014-05-16Not applicableUs
Keppra XRtablet, film coated, extended release750 mg/1oralRx Pak Division Of Mc Kesson Corporation2014-05-16Not applicableUs
Keppra XRtablet, film coated, extended release500 mg/1oralUCB, Inc.2008-09-24Not applicableUs
Keppra XRtablet, film coated, extended release750 mg/1oralUCB, Inc.2009-04-01Not applicableUs
Levetiracetamtablet500 mgoralPharmascience IncNot applicableNot applicableCanada
Levetiracetamtablet250 mgoralSanis Health Inc2010-07-26Not applicableCanada
Levetiracetaminjection15 mg/mLintravenousMylan Institutional LLC2011-11-10Not applicableUs
Levetiracetamtablet500 mgoralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Levetiracetamtablet500 mgoralSivem Pharmaceuticals Ulc2015-07-22Not applicableCanada
Levetiracetamtablet750 mgoralPharmascience IncNot applicableNot applicableCanada
Levetiracetamtablet250 mgoralJubilant Generics LimitedNot applicableNot applicableCanada
Levetiracetamtablet500 mgoralSanis Health Inc2010-07-26Not applicableCanada
Levetiracetamtablet750 mgoralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Levetiracetamtablet750 mgoralSivem Pharmaceuticals Ulc2015-07-22Not applicableCanada
Levetiracetaminjection5 mg/mLintravenousMylan Institutional LLC2011-11-10Not applicableUs
Levetiracetamtablet750 mgoralSanis Health Inc2010-07-26Not applicableCanada
Levetiracetamtablet500 mgoralJubilant Generics LimitedNot applicableNot applicableCanada
Levetiracetamtablet250 mgoralPharmascience IncNot applicableNot applicableCanada
Levetiracetamtablet250 mgoralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Levetiracetaminjection10 mg/mLintravenousMylan Institutional LLC2011-11-10Not applicableUs
Levetiracetamtablet250 mgoralSivem Pharmaceuticals Ulc2015-07-22Not applicableCanada
Levetiracetamtablet750 mgoralJubilant Generics LimitedNot applicableNot applicableCanada
Levetiracetam Tabletstablet750 mgoralAccord Healthcare Inc2013-03-20Not applicableCanada
Levetiracetam Tabletstablet250 mgoralAccord Healthcare Inc2013-03-20Not applicableCanada
Levetiracetam Tabletstablet500 mgoralAccord Healthcare Inc2013-03-20Not applicableCanada
Nat-levetiracetamtablet250 mgoralNatco Pharma (Canada) Inc2015-07-22Not applicableCanada
Nat-levetiracetamtablet500 mgoralNatco Pharma (Canada) Inc2015-07-22Not applicableCanada
Nat-levetiracetamtablet750 mgoralNatco Pharma (Canada) Inc2015-07-22Not applicableCanada
Novo-levetiracetamtablet750 mgoralNovopharm LimitedNot applicableNot applicableCanada
Nu-levetiracetamtablet250 mgoralNu Pharm IncNot applicableNot applicableCanada
Nu-levetiracetamtablet500 mgoralNu Pharm IncNot applicableNot applicableCanada
Nu-levetiracetamtablet750 mgoralNu Pharm IncNot applicableNot applicableCanada
PHL-levetiracetamtablet500 mgoralPharmel Inc2008-04-16Not applicableCanada
PHL-levetiracetamtablet750 mgoralPharmel Inc2008-04-16Not applicableCanada
PHL-levetiracetamtablet250 mgoralPharmel Inc2008-04-16Not applicableCanada
PMS-levetiracetamtablet500 mgoralPharmascience Inc2007-06-07Not applicableCanada
PMS-levetiracetamtablet750 mgoralPharmascience Inc2007-06-07Not applicableCanada
PMS-levetiracetamtablet250 mgoralPharmascience Inc2007-06-07Not applicableCanada
Priva-levetiracetamtablet250 mgoralPharmapar IncNot applicableNot applicableCanada
Priva-levetiracetamtablet500 mgoralPharmapar IncNot applicableNot applicableCanada
Priva-levetiracetamtablet750 mgoralPharmapar IncNot applicableNot applicableCanada
Pro-levetiracetam - 250tablet250 mgoralPro Doc Limitee2013-06-06Not applicableCanada
Pro-levetiracetam - 500tablet500 mgoralPro Doc Limitee2009-06-16Not applicableCanada
Pro-levetiracetam - 750tablet750 mgoralPro Doc Limitee2009-10-08Not applicableCanada
Ran-levetiracetamtablet500 mgoralRanbaxy Pharmaceuticals Canada Inc.2013-03-22Not applicableCanada
Ran-levetiracetamtablet750 mgoralRanbaxy Pharmaceuticals Canada Inc.2013-03-22Not applicableCanada
Ran-levetiracetamtablet250 mgoralRanbaxy Pharmaceuticals Canada Inc.2013-03-22Not applicableCanada
Spritamtablet, for suspension750 mg/1oralAprecia Pharmaceuticals Company2016-02-05Not applicableUs
Spritamtablet, for suspension1000 mg/1oralAprecia Pharmaceuticals Company2016-02-05Not applicableUs
Spritamtablet, for suspension250 mg/1oralAprecia Pharmaceuticals Company2016-02-05Not applicableUs
Spritamtablet, for suspension500 mg/1oralAprecia Pharmaceuticals Company2016-02-05Not applicableUs
Torrent-levetiracetamtablet750 mgoralTorrent Pharmaceuticals LimitedNot applicableNot applicableCanada
Torrent-levetiracetamtablet250 mgoralTorrent Pharmaceuticals LimitedNot applicableNot applicableCanada
Torrent-levetiracetamtablet500 mgoralTorrent Pharmaceuticals LimitedNot applicableNot applicableCanada
Van-levetiracetamtablet750 mgoralVanc Pharmaceuticals Inc2016-04-04Not applicableCanada
Van-levetiracetamtablet250 mgoralVanc Pharmaceuticals Inc2016-04-04Not applicableCanada
Van-levetiracetamtablet500 mgoralVanc Pharmaceuticals Inc2016-04-04Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-levetiracetamtablet250 mgoralApotex Inc2006-10-20Not applicableCanada
Apo-levetiracetamtablet500 mgoralApotex Inc2006-10-20Not applicableCanada
Apo-levetiracetamtablet750 mgoralApotex Inc2006-10-20Not applicableCanada
Levetiracetamtablet, film coated250 mg/1oralSolco Healthcare US, LLC2012-09-11Not applicableUs
Levetiracetamtablet, film coated750 mg/1oralKaralex Pharma LLC2011-09-01Not applicableUs
Levetiracetamtablet500 mg/1oralREMEDYREPACK INC.2011-10-12Not applicableUs
Levetiracetamsolution100 mg/mLoralQualitest Pharmaceuticals2012-04-11Not applicableUs
Levetiracetamtablet, film coated500 mg/1oralMylan Institutional Inc.2008-11-04Not applicableUs
Levetiracetamtablet, film coated750 mg/1oralLucid Pharma Llc2014-11-06Not applicableUs
Levetiracetamsolution100 mg/mLoralPharmaceutical Associates, Inc.2009-02-11Not applicableUs
Levetiracetamtablet1000 mg/1oralDr. Reddy's Laboratories Limited2009-01-15Not applicableUs
Levetiracetamtablet750 mg/1oralTorrent Pharmaceuticals Limited2009-01-15Not applicableUs
Levetiracetamtablet, film coated500 mg/1oralREMEDYREPACK INC.2015-02-26Not applicableUs
Levetiracetamtablet, film coated250 mg/1oralAccord Healthcare Inc.2011-03-14Not applicableUs
Levetiracetamtablet, film coated500 mg/1oralBoca Pharmacal, LLC2014-09-12Not applicableUs
Levetiracetamtablet, film coated250 mg/1oralCamber Pharmaceuticals2012-01-09Not applicableUs
Levetiracetamtablet, film coated750 mg/1oralHetero Drugs Ltd.,2010-10-08Not applicableUs
Levetiracetamtablet, film coated750 mg/1oralAmerican Health Packaging2012-04-02Not applicableUs
Levetiracetamtablet750 mg/1oralExelan Pharmaceuticals, Inc.2009-01-15Not applicableUs
Levetiracetaminjection, solution500 mg/5mLintravenousAuro Medics Pharma Llc2016-02-01Not applicableUs
Levetiracetamtablet, film coated750 mg/1oralCardinal Health2009-11-192015-12-29Us
Levetiracetamtablet, film coated500 mg/1oralREMEDYREPACK INC.2016-02-25Not applicableUs
Levetiracetamtablet, film coated750 mg/1oralLupin Pharmaceuticals, Inc.2009-01-01Not applicableUs
Levetiracetamtablet, film coated250 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-01-23Not applicableUs
Levetiracetamtablet, film coated750 mg/1oralSecan Pharmaceuticals, Inc.2015-12-18Not applicableUs
Levetiracetamtablet, film coated750 mg/1oralMylan Pharmaceuticals Inc.2008-11-04Not applicableUs
Levetiracetamtablet, film coated500 mg/1oralAv Pak2009-03-20Not applicableUs
Levetiracetamtablet250 mg/1oralBreckenridge Pharmaceutical, Inc.2011-11-01Not applicableUs
Levetiracetamsolution100 mg/mLoralRoxane Laboratories, Inc2009-01-15Not applicableUs
Levetiracetamtablet500 mg/1oralPhysicians Total Care, Inc.2009-10-15Not applicableUs
Levetiracetamtablet250 mg/1oralMajor Pharmaceuticals2013-08-02Not applicableUs
Levetiracetamtablet500 mg/1oralSTAT Rx USA LLC2009-01-15Not applicableUs
Levetiracetaminjection100 mg/mLintravenousSun Pharmaceutical Industries Limited2010-06-17Not applicableUs
Levetiracetamtablet250 mg/1oralRebel Distributors Corp2009-10-15Not applicableUs
Levetiracetamtablet, film coated250 mg/1oralAurobindo Pharma Limited2009-01-15Not applicableUs
Levetiracetamtablet, extended release750 mg/1oralBlue Point Laboratories2014-02-13Not applicableUs
Levetiracetamtablet, extended release500 mg/1oralLupin Pharmaceuticals, Inc.2011-09-12Not applicableUs
Levetiracetamtablet, film coated500 mg/1oralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
Levetiracetamtablet, film coated, extended release750 mg/1oralActavis Elizabeth LLC2011-09-12Not applicableUs
Levetiracetamtablet, film coated500 mg/1oralClinical Solutions Wholesale2009-01-01Not applicableUs
Levetiracetamtablet, film coated500 mg/1oralTrigen Laboratories, Inc.2012-03-31Not applicableUs
Levetiracetamtablet, film coated500 mg/1oralREMEDYREPACK INC.2015-11-12Not applicableUs
Levetiracetamsolution100 mg/mLoralAtlantic Biologicals Corps2009-10-27Not applicableUs
Levetiracetamtablet, film coated500 mg/1oralAmneal Pharmaceuticals of New York, LLC2013-02-28Not applicableUs
Levetiracetamtablet, film coated500 mg/1oralMethapharm, Inc.2010-10-18Not applicableUs
Levetiracetamtablet, film coated750 mg/1oralAmerican Health Packaging2014-12-15Not applicableUs
Levetiracetamtablet, film coated1000 mg/1oralPrinston Pharmaceutical Inc.2012-09-11Not applicableUs
Levetiracetamtablet, film coated500 mg/1oralLUPIN LIMITED2009-01-01Not applicableUs
Levetiracetamtablet, film coated250 mg/1oralCardinal Health2012-08-29Not applicableUs
Levetiracetamtablet, film coated250 mg/1oralRebel Distributors Corp2009-01-01Not applicableUs
Levetiracetamtablet250 mg/1oralREMEDYREPACK INC.2011-10-17Not applicableUs
Levetiracetamtablet, film coated500 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2013-02-06Not applicableUs
Levetiracetamtablet, film coated1000 mg/1oralTaro Pharmaceuticals U.S.A., Inc.2010-02-01Not applicableUs
Levetiracetamtablet, film coated750 mg/1oralUnit Dose Services2009-01-01Not applicableUs
Levetiracetamsolution100 mg/mLoralBreckenridge Pharmaceutical, Inc.2013-11-19Not applicableUs
Levetiracetamtablet, film coated, extended release750 mg/1oralTeva Pharmaceuticals USA Inc2011-09-14Not applicableUs
Levetiracetamtablet250 mg/1oralDr. Reddy's Laboratories Limited2009-01-15Not applicableUs
Levetiracetamtablet, film coated, extended release750 mg/1oralApotex Corp.2011-09-12Not applicableUs
Levetiracetamtablet, film coated750 mg/1oralNorth Star Rx Llc2009-01-15Not applicableUs
Levetiracetamtablet, film coated750 mg/1oralbryant ranch prepack2009-01-01Not applicableUs
Levetiracetamsolution100 mg/mLoralLLC Federal Solutions2013-09-24Not applicableUs
Levetiracetamtablet, film coated1000 mg/1oralAurobindo Pharma Limited2009-01-15Not applicableUs
Levetiracetamtablet, film coated750 mg/1oralBlue Point Laboratories2014-02-24Not applicableUs
Levetiracetamtablet, film coated750 mg/1oralMc Kesson Contract Packaging2011-11-23Not applicableUs
Levetiracetamtablet, film coated250 mg/1oralREMEDYREPACK INC.2016-03-14Not applicableUs
Levetiracetamtablet, film coated750 mg/1oralAjanta Pharma Limited2015-08-10Not applicableUs
Levetiracetamtablet, film coated500 mg/1oralLotus Pharmaceutical Co., Ltd. Nantou Plant2015-03-062016-01-09Us
Levetiracetamtablet, film coated, extended release500 mg/1oralSun Pharma Global FZE2013-09-09Not applicableUs
Levetiracetaminjection, solution, concentrate100 mg/mLintravenousAmerican Regent, Inc.2012-02-21Not applicableUs
Levetiracetamtablet, film coated250 mg/1oralPrinston Pharmaceutical Inc.2012-09-11Not applicableUs
Levetiracetamtablet, extended release500 mg/1oralLUPIN LIMITED2011-09-12Not applicableUs
Levetiracetamtablet, film coated500 mg/1oralSolco Healthcare US, LLC2012-09-11Not applicableUs
Levetiracetamtablet, film coated1000 mg/1oralKaralex Pharma LLC2011-09-01Not applicableUs
Levetiracetamtablet, film coated, extended release500 mg/1oralQualitest Pharmaceuticals2012-07-20Not applicableUs
Levetiracetamtablet, film coated750 mg/1oralMylan Institutional Inc.2008-11-04Not applicableUs
Levetiracetamtablet, film coated1000 mg/1oralLucid Pharma Llc2014-11-06Not applicableUs
Levetiracetaminjection100 mg/mLintravenousWest Ward Pharmaceuticals Corp2015-06-01Not applicableUs
Levetiracetamtablet, film coated500 mg/1oralCardinal Health2011-09-26Not applicableUs
Levetiracetamtablet1000 mg/1oralTorrent Pharmaceuticals Limited2009-01-15Not applicableUs
Levetiracetamtablet, film coated250 mg/1oralREMEDYREPACK INC.2015-06-19Not applicableUs
Levetiracetamtablet, film coated500 mg/1oralAccord Healthcare Inc.2011-03-14Not applicableUs
Levetiracetamtablet, film coated750 mg/1oralBoca Pharmacal, LLC2014-09-12Not applicableUs
Levetiracetamtablet, film coated500 mg/1oralCamber Pharmaceuticals2012-01-09Not applicableUs
Levetiracetamtablet, film coated1000 mg/1oralHetero Drugs Ltd.,2010-10-08Not applicableUs
Levetiracetamtablet, film coated1000 mg/1oralAmerican Health Packaging2010-12-29Not applicableUs
Levetiracetamtablet, film coated1000 mg/1oralBlue Point Laboratories2014-02-24Not applicableUs
Levetiracetamtablet, extended release750 mg/1oralLupin Pharmaceuticals, Inc.2011-09-12Not applicableUs
Levetiracetamtablet, film coated750 mg/1oralREMEDYREPACK INC.2016-01-07Not applicableUs
Levetiracetamtablet, film coated1000 mg/1oralREMEDYREPACK INC.2016-03-01Not applicableUs
Levetiracetamtablet, film coated1000 mg/1oralLupin Pharmaceuticals, Inc.2009-01-15Not applicableUs
Levetiracetamtablet, film coated500 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-01-23Not applicableUs
Levetiracetamtablet, film coated1000 mg/1oralSecan Pharmaceuticals, Inc.2015-12-18Not applicableUs
Levetiracetamtablet, film coated1000 mg/1oralMylan Pharmaceuticals Inc.2009-12-10Not applicableUs
Levetiracetamtablet, film coated750 mg/1oralAv Pak2009-03-20Not applicableUs
Levetiracetamtablet500 mg/1oralBreckenridge Pharmaceutical, Inc.2011-11-01Not applicableUs
Levetiracetamtablet, film coated500 mg/1oralTeva Pharmaceuticals USA Inc2009-01-15Not applicableUs
Levetiracetamtablet1000 mg/1oralPhysicians Total Care, Inc.2009-10-15Not applicableUs
Levetiracetamtablet500 mg/1oralMajor Pharmaceuticals2009-07-31Not applicableUs
Levetiracetamtablet750 mg/1oralSTAT Rx USA LLC2009-01-15Not applicableUs
Levetiracetaminjection, solution100 mg/mLintravenousFresenius Kabi USA, LLC2010-06-03Not applicableUs
Levetiracetamtablet750 mg/1oralRebel Distributors Corp2009-10-15Not applicableUs
Levetiracetamtablet, film coated500 mg/1oralAurobindo Pharma Limited2009-01-15Not applicableUs
Levetiracetamtablet, extended release500 mg/1oralPar Pharmaceutical Inc.2011-09-13Not applicableUs
Levetiracetamtablet, film coated750 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2013-02-06Not applicableUs
Levetiracetamtablet, film coated250 mg/1oralTaro Pharmaceuticals U.S.A., Inc.2010-02-01Not applicableUs
Levetiracetamtablet, film coated500 mg/1oralState of Florida DOH Central Pharmacy2013-09-01Not applicableUs
Levetiracetamtablet, film coated, extended release500 mg/1oralActavis Elizabeth LLC2011-09-12Not applicableUs
Levetiracetamtablet, film coated750 mg/1oralClinical Solutions Wholesale2009-01-01Not applicableUs
Levetiracetaminjection, solution100 mg/mLintravenousNexus Pharmaceuticals Inc2010-06-03Not applicableUs
Levetiracetamtablet, film coated500 mg/1oralREMEDYREPACK INC.2015-11-12Not applicableUs
Levetiracetamsolution100 mg/mLoralAtlantic Biologicals Corps2009-01-16Not applicableUs
Levetiracetamtablet, film coated750 mg/1oralAmneal Pharmaceuticals of New York, LLC2013-02-28Not applicableUs
Levetiracetamtablet, film coated250 mg/1oralAidarex Pharmaceuticals LLC2009-01-01Not applicableUs
Levetiracetamtablet, film coated750 mg/1oralMethapharm, Inc.2010-10-18Not applicableUs
Levetiracetamtablet, film coated1000 mg/1oralAmerican Health Packaging2014-12-15Not applicableUs
Levetiracetamtablet, film coated250 mg/1oralTeva Pharmaceuticals USA Inc2009-01-152015-11-30Us
Levetiracetamtablet, film coated750 mg/1oralLUPIN LIMITED2009-01-01Not applicableUs
Levetiracetamtablet, film coated500 mg/1oralCardinal Health2012-08-29Not applicableUs
Levetiracetamtablet500 mg/1oralPd Rx Pharmaceuticals, Inc.2009-01-15Not applicableUs
Levetiracetamtablet, film coated250 mg/1oralKaralex Pharma LLC2011-09-01Not applicableUs
Levetiracetamtablet, film coated, extended release750 mg/1oralSun Pharma Global FZE2013-09-09Not applicableUs
Levetiracetamtablet, film coated, extended release500 mg/1oralActavis Pharma, Inc.2011-09-12Not applicableUs
Levetiracetamtablet, film coated500 mg/1oralUnit Dose Services2009-01-01Not applicableUs
Levetiracetamtablet, film coated250 mg/1oralLucid Pharma Llc2014-11-06Not applicableUs
Levetiracetamsolution100 mg/mLoralPharmaceutical Associates, Inc.2015-06-04Not applicableUs
Levetiracetamtablet500 mg/1oralDr. Reddy's Laboratories Limited2009-01-15Not applicableUs
Levetiracetamtablet250 mg/1oralTorrent Pharmaceuticals Limited2009-01-15Not applicableUs
Levetiracetamtablet, film coated, extended release1000 mg/1oralApotex Corp.2015-02-25Not applicableUs
Levetiracetamtablet, film coated1000 mg/1oralNorth Star Rx Llc2009-01-15Not applicableUs
Levetiracetamsolution100 mg/mLoralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2011-11-01Not applicableUs
Levetiracetaminjection, solution, concentrate500 mg/5mLintravenousSagent Pharmaceuticals2013-11-01Not applicableUs
Levetiracetamtablet, film coated250 mg/1oralHetero Drugs Ltd.,2010-10-08Not applicableUs
Levetiracetamtablet, film coated250 mg/1oralAmerican Health Packaging2010-01-28Not applicableUs
Levetiracetamtablet250 mg/1oralExelan Pharmaceuticals, Inc.2009-01-15Not applicableUs
Levetiracetamsolution100 mg/mLoralSilarx Pharmaceuticals, Inc.2009-04-03Not applicableUs
Levetiracetamtablet, film coated1000 mg/1oralAjanta Pharma Limited2015-08-10Not applicableUs
Levetiracetamtablet, film coated750 mg/1oralCamber Pharmaceuticals2012-01-09Not applicableUs
Levetiracetamsolution100 mg/mLoralVista Pharm, Inc2010-01-25Not applicableUs
Levetiracetamtablet, film coated250 mg/1oralAmerican Health Packaging2014-12-15Not applicableUs
Levetiracetamtablet, film coated500 mg/1oralPrinston Pharmaceutical Inc.2012-09-11Not applicableUs
Levetiracetamtablet, extended release750 mg/1oralLUPIN LIMITED2011-09-12Not applicableUs
Levetiracetamtablet, film coated750 mg/1oralSolco Healthcare US, LLC2012-09-11Not applicableUs
Levetiracetamtablet, film coated500 mg/1oralRebel Distributors Corp2011-09-01Not applicableUs
Levetiracetamtablet250 mg/1oralREMEDYREPACK INC.2011-12-07Not applicableUs
Levetiracetamtablet, film coated, extended release750 mg/1oralQualitest Pharmaceuticals2012-07-20Not applicableUs
Levetiracetamtablet, film coated1000 mg/1oralMylan Institutional Inc.2010-03-24Not applicableUs
Levetiracetamtablet, film coated500 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Levetiracetaminjection100 mg/mLintravenousWest Ward Pharmaceuticals Corp2011-10-13Not applicableUs
Levetiracetamsolution100 mg/mLoralCardinal Health2011-11-01Not applicableUs
Levetiracetamtablet, extended release500 mg/1oralTorrent Pharmaceuticals Limited2012-05-29Not applicableUs
Levetiracetamtablet, film coated250 mg/1oralREMEDYREPACK INC.2015-07-03Not applicableUs
Levetiracetamtablet, film coated750 mg/1oralAccord Healthcare Inc.2011-03-14Not applicableUs
Levetiracetamtablet, film coated500 mg/1oralTYA Pharmaceuticals2009-01-01Not applicableUs
Levetiracetamtablet, film coated250 mg/1oralNorth Star Rx Llc2009-01-15Not applicableUs
Levetiracetamtablet, film coated500 mg/1oralbryant ranch prepack2009-01-01Not applicableUs
Levetiracetamtablet, film coated250 mg/1oralREMEDYREPACK INC.2013-03-18Not applicableUs
Levetiracetamtablet, film coated750 mg/1oralAurobindo Pharma Limited2009-01-15Not applicableUs
Levetiracetamtablet, film coated250 mg/1oralBlue Point Laboratories2014-02-24Not applicableUs
Levetiracetamtablet, film coated250 mg/1oralDispensing Solutions, Inc.2009-01-15Not applicableUs
Levetiracetamsolution100 mg/mLoralAtlantic Biologicals Corps2012-02-28Not applicableUs
Levetiracetamtablet, film coated250 mg/1oralAjanta Pharma Limited2015-08-10Not applicableUs
Levetiracetamtablet, film coated750 mg/1oralLake Eire Medical & Surgical Supply DBA Quality Care Products LLC2011-11-14Not applicableUs
Levetiracetamtablet, film coated, extended release500 mg/1oralSolco Healthcare US, LLC2014-05-01Not applicableUs
Levetiracetaminjection100 mg/mLintravenousHospira, Inc.2012-04-06Not applicableUs
Levetiracetamsolution100 mg/mLoralHi Tech Pharmacal Co., Inc.2012-02-28Not applicableUs
Levetiracetamtablet750 mg/1oralBreckenridge Pharmaceutical, Inc.2011-11-01Not applicableUs
Levetiracetamtablet, film coated750 mg/1oralTeva Pharmaceuticals USA Inc2009-01-152016-02-29Us
Levetiracetamtablet750 mg/1oralPhysicians Total Care, Inc.2011-06-07Not applicableUs
Levetiracetamtablet750 mg/1oralMajor Pharmaceuticals2013-08-02Not applicableUs
Levetiracetamsolution100 mg/mLoralMorton Grove Pharmaceuticals, Inc.2010-03-18Not applicableUs
Levetiracetamtablet, film coated500 mg/1oralPd Rx Pharmaceuticals, Inc.2009-01-01Not applicableUs
Levetiracetamtablet, extended release750 mg/1oralPar Pharmaceutical Inc.2011-09-13Not applicableUs
Levetiracetamtablet1000 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2009-01-15Not applicableUs
Levetiracetamtablet, film coated500 mg/1oralTaro Pharmaceuticals U.S.A., Inc.2010-02-01Not applicableUs
Levetiracetamtablet, film coated500 mg/1oralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs
Levetiracetamtablet, film coated250 mg/1oralMylan Pharmaceuticals Inc.2008-11-04Not applicableUs
Levetiracetamtablet, film coated1000 mg/1oralClinical Solutions Wholesale2009-01-15Not applicableUs
Levetiracetamsolution100 mg/mLoralOrit Laboratories LLC2012-04-30Not applicableUs
Levetiracetamtablet250 mg/1oralDIRECT RX2014-01-01Not applicableUs
Levetiracetamtablet500 mg/1oralRebel Distributors Corp2009-10-15Not applicableUs
Levetiracetamtablet, film coated1000 mg/1oralAmneal Pharmaceuticals of New York, LLC2013-02-28Not applicableUs
Levetiracetamtablet, film coated500 mg/1oralAidarex Pharmaceuticals LLC2009-01-01Not applicableUs
Levetiracetamtablet, film coated1000 mg/1oralMethapharm, Inc.2010-10-18Not applicableUs
Levetiracetamsolution100 mg/mLoralLupin Pharmaceuticals, Inc.2014-11-01Not applicableUs
Levetiracetamtablet, film coated1000 mg/1oralTeva Pharmaceuticals USA Inc2009-01-152015-11-30Us
Levetiracetamtablet, film coated1000 mg/1oralLUPIN LIMITED2009-01-15Not applicableUs
Levetiracetamtablet, film coated250 mg/1oralLupin Pharmaceuticals, Inc.2009-01-01Not applicableUs
Levetiracetamtablet, film coated500 mg/1oralKaralex Pharma LLC2011-09-01Not applicableUs
Levetiracetamtablet750 mg/1oralREMEDYREPACK INC.2010-11-08Not applicableUs
Levetiracetamtablet, film coated, extended release750 mg/1oralActavis Pharma, Inc.2011-09-12Not applicableUs
Levetiracetamtablet, film coated250 mg/1oralMylan Institutional Inc.2008-11-04Not applicableUs
Levetiracetamtablet, film coated500 mg/1oralLucid Pharma Llc2014-11-06Not applicableUs
Levetiracetamsolution100 mg/mLoralPharmaceutical Associates, Inc.2015-06-04Not applicableUs
Levetiracetamtablet750 mg/1oralDr. Reddy's Laboratories Limited2009-01-15Not applicableUs
Levetiracetamtablet500 mg/1oralTorrent Pharmaceuticals Limited2009-01-15Not applicableUs
Levetiracetamtablet, film coated250 mg/1oralREMEDYREPACK INC.2015-03-03Not applicableUs
Levetiracetamsolution100 mg/mLoralNorth Star Rx Llc2009-01-15Not applicableUs
Levetiracetamtablet, film coated250 mg/1oralBoca Pharmacal, LLC2014-09-12Not applicableUs
Levetiracetamsolution100 mg/mLoralTris Pharma Inc2012-10-19Not applicableUs
Levetiracetamtablet, film coated500 mg/1oralHetero Drugs Ltd.,2010-10-08Not applicableUs
Levetiracetamtablet, film coated500 mg/1oralAmerican Health Packaging2010-01-28Not applicableUs
Levetiracetamtablet500 mg/1oralExelan Pharmaceuticals, Inc.2009-01-15Not applicableUs
Levetiracetamsolution100 mg/mLoralSandoz Inc.2009-01-15Not applicableUs
Levetiracetamtablet, extended release750 mg/1oralTorrent Pharmaceuticals Limited2012-05-29Not applicableUs
Levetiracetamtablet, film coated500 mg/1oralREMEDYREPACK INC.2015-10-09Not applicableUs
Levetiracetamtablet, film coated1000 mg/1oralAccord Healthcare Inc.2011-03-14Not applicableUs
Levetiracetamtablet, film coated250 mg/1oralAmneal Pharmaceuticals of New York, LLC2013-02-28Not applicableUs
Levetiracetamtablet, film coated1000 mg/1oralCamber Pharmaceuticals2012-01-09Not applicableUs
Levetiracetamtablet, film coated250 mg/1oralMethapharm, Inc.2010-10-18Not applicableUs
Levetiracetamtablet, film coated500 mg/1oralAmerican Health Packaging2014-12-15Not applicableUs
Levetiracetamtablet, film coated750 mg/1oralPrinston Pharmaceutical Inc.2012-09-11Not applicableUs
Levetiracetamtablet, film coated250 mg/1oralLUPIN LIMITED2009-01-01Not applicableUs
Levetiracetamtablet, film coated1000 mg/1oralSolco Healthcare US, LLC2012-09-11Not applicableUs
Levetiracetamtablet, film coated1000 mg/1oralRebel Distributors Corp2011-09-01Not applicableUs
Levetiracetamtablet500 mg/1oralREMEDYREPACK INC.2011-09-21Not applicableUs
Levetiracetamtablet, film coated250 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2008-11-04Not applicableUs
Levetiracetamsolution100 mg/mLoralTaro Pharmaceuticals U.S.A., Inc.2009-02-10Not applicableUs
Levetiracetamtablet, film coated500 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Levetiracetamtablet, film coated1000 mg/1oralActavis Elizabeth LLC2011-04-04Not applicableUs
Levetiracetamsolution100 mg/mLoralCardinal Health2009-09-20Not applicableUs
Levetiracetamtablet, film coated, extended release500 mg/1oralTeva Pharmaceuticals USA Inc2011-09-14Not applicableUs
Levetiracetamtablet, film coated, extended release500 mg/1oralPhysicians Total Care, Inc.2011-11-22Not applicableUs
Levetiracetamtablet, film coated, extended release500 mg/1oralApotex Corp.2011-09-12Not applicableUs
Levetiracetamtablet, film coated500 mg/1oralNorth Star Rx Llc2009-01-15Not applicableUs
Levetiracetamtablet, film coated250 mg/1oralbryant ranch prepack2009-01-01Not applicableUs
Levetiracetamtablet, film coated500 mg/1oralREMEDYREPACK INC.2013-05-06Not applicableUs
Levetiracetamsolution100 mg/mLoralAurobindo Pharma Limited2009-01-15Not applicableUs
Levetiracetamtablet, film coated500 mg/1oralBlue Point Laboratories2014-02-24Not applicableUs
Levetiracetamtablet, film coated500 mg/1oralMc Kesson Contract Packaging2011-10-12Not applicableUs
Levetiracetamtablet, film coated1000 mg/1oralREMEDYREPACK INC.2016-01-12Not applicableUs
Levetiracetamsolution100 mg/mLoralCardinal Health2015-06-04Not applicableUs
Levetiracetamtablet, film coated500 mg/1oralAjanta Pharma Limited2015-08-10Not applicableUs
Levetiracetaminjection, solution, concentrate500 mg/5mLintravenousX Gen Pharmaceuticals, Inc.2011-08-05Not applicableUs
Levetiracetamtablet, film coated, extended release750 mg/1oralSolco Healthcare US, LLC2014-05-01Not applicableUs
Levetiracetamsolution100 mg/mLoralActavis Mid Atlantic LLC2009-01-15Not applicableUs
Levetiracetamtablet, film coated250 mg/1oralUnit Dose Services2009-01-01Not applicableUs
Levetiracetamtablet1000 mg/1oralBreckenridge Pharmaceutical, Inc.2011-11-01Not applicableUs
Levetiracetamtablet, film coated250 mg/1oralSecan Pharmaceuticals, Inc.2015-12-18Not applicableUs
Levetiracetamtablet, film coated250 mg/1oralAv Pak2009-03-20Not applicableUs
Levetiracetamtablet1000 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2009-01-15Not applicableUs
Levetiracetamtablet, film coated750 mg/1oralTaro Pharmaceuticals U.S.A., Inc.2010-02-01Not applicableUs
Levetiracetamtablet, film coated750 mg/1oralState of Florida DOH Central Pharmacy2014-11-01Not applicableUs
Levetiracetamtablet, film coated500 mg/1oralMylan Pharmaceuticals Inc.2008-11-04Not applicableUs
Levetiracetamsolution100 mg/5mLoralGolden State Medical Supply, Inc.2009-02-10Not applicableUs
Levetiracetamtablet250 mg/1oralSTAT Rx USA LLC2009-01-15Not applicableUs
Levetiracetamtablet, film coated500 mg/1oralDIRECT RX2014-01-01Not applicableUs
Levetiracetamtablet1000 mg/1oralRebel Distributors Corp2009-10-15Not applicableUs
Levetiracetamsolution100 mg/mLoralAmneal Pharmaceuticals of New York, LLC2009-10-27Not applicableUs
Levetiracetamtablet, film coated750 mg/1oralAidarex Pharmaceuticals LLC2009-01-01Not applicableUs
Levetiracetamtablet, extended release500 mg/1oralBlue Point Laboratories2014-02-13Not applicableUs
Levetiracetamsolution100 mg/mLoralLupin Pharmaceuticals, Inc.2013-01-25Not applicableUs
Levetiracetamtablet, film coated500 mg/1oralCardinal Health2009-11-192015-12-29Us
Levetiracetamtablet, film coated750 mg/1oralREMEDYREPACK INC.2016-02-12Not applicableUs
Levetiracetamtablet, film coated500 mg/1oralLupin Pharmaceuticals, Inc.2009-01-01Not applicableUs
Levetiracetam AccordFilm-coated tablet250 mgOral useAccord Healthcare Ltd  2011-10-03Not applicableEu
Levetiracetam AccordFilm-coated tablet750 mgOral useAccord Healthcare Ltd  2011-10-03Not applicableEu
Levetiracetam AccordFilm-coated tablet500 mgOral useAccord Healthcare Ltd  2011-10-03Not applicableEu
Levetiracetam AccordFilm-coated tablet500 mgOral useAccord Healthcare Ltd  2011-10-03Not applicableEu
Levetiracetam AccordFilm-coated tablet1000 mgOral useAccord Healthcare Ltd  2011-10-03Not applicableEu
Levetiracetam AccordFilm-coated tablet Page 2 of 21000 mgOral useAccord Healthcare Ltd  2011-10-03Not applicableEu
Levetiracetam AccordFilm-coated tablet250 mgOral useAccord Healthcare Ltd  2011-10-03Not applicableEu
Levetiracetam AccordFilm-coated tablet750 mgOral useAccord Healthcare Ltd  2011-10-03Not applicableEu
Levetiracetam AccordFilm-coated tablet750 mgOral useAccord Healthcare Ltd  2011-10-03Not applicableEu
Levetiracetam AccordFilm-coated tablet500 mgOral useAccord Healthcare Ltd  2011-10-03Not applicableEu
Levetiracetam AccordFilm-coated tablet250 mgOral useAccord Healthcare Ltd  2011-10-03Not applicableEu
Levetiracetam AccordFilm-coated tablet250 mgOral useAccord Healthcare Ltd  2011-10-03Not applicableEu
Levetiracetam AccordFilm-coated tablet750 mgOral useAccord Healthcare Ltd  2011-10-03Not applicableEu
Levetiracetam AccordFilm-coated tablet Page 1 of 2500 mgOral useAccord Healthcare Ltd  2011-10-03Not applicableEu
Levetiracetam AccordFilm-coated tablet500 mgOral useAccord Healthcare Ltd  2011-10-03Not applicableEu
Levetiracetam AccordFilm-coated tablet1000 mgOral useAccord Healthcare Ltd  2011-10-03Not applicableEu
Levetiracetam AccordFilm-coated tablet250 mgOral useAccord Healthcare Ltd  2011-10-03Not applicableEu
Levetiracetam AccordFilm-coated tablet1000 mgOral useAccord Healthcare Ltd  2011-10-03Not applicableEu
Levetiracetam AccordFilm-coated tablet750 mgOral useAccord Healthcare Ltd  2011-10-03Not applicableEu
Levetiracetam AccordFilm-coated tablet750 mgOral useAccord Healthcare Ltd  2011-10-03Not applicableEu
Levetiracetam AccordFilm-coated tablet250 mgOral useAccord Healthcare Ltd  2011-10-03Not applicableEu
Levetiracetam AccordFilm-coated tablet250 mgOral useAccord Healthcare Ltd  2011-10-03Not applicableEu
Levetiracetam AccordFilm-coated tablet750 mgOral useAccord Healthcare Ltd  2011-10-03Not applicableEu
Levetiracetam AccordFilm-coated tablet500 mgOral useAccord Healthcare Ltd  2011-10-03Not applicableEu
Levetiracetam AccordFilm-coated tablet500 mgOral useAccord Healthcare Ltd  2011-10-03Not applicableEu
Levetiracetam AccordFilm-coated tablet1000 mgOral useAccord Healthcare Ltd  2011-10-03Not applicableEu
Levetiracetam AccordFilm-coated tablet500 mgOral useAccord Healthcare Ltd  2011-10-03Not applicableEu
Levetiracetam AccordFilm-coated tablet1000 mgOral useAccord Healthcare Ltd  2011-10-03Not applicableEu
Levetiracetam AccordFilm-coated tablet1000 mgOral useAccord Healthcare Ltd  2011-10-03Not applicableEu
Levetiracetam AccordFilm-coated tablet250 mgOral useAccord Healthcare Ltd  2011-10-03Not applicableEu
Levetiracetam AccordFilm-coated tablet250 mgOral useAccord Healthcare Ltd  2011-10-03Not applicableEu
Levetiracetam AccordFilm-coated tablet750 mgOral useAccord Healthcare Ltd  2011-10-03Not applicableEu
Levetiracetam AccordFilm-coated tablet250 mgOral useAccord Healthcare Ltd  2011-10-03Not applicableEu
Levetiracetam AccordFilm-coated tablet750 mgOral useAccord Healthcare Ltd  2011-10-03Not applicableEu
Levetiracetam AccordFilm-coated tablet750 mgOral useAccord Healthcare Ltd  2011-10-03Not applicableEu
Levetiracetam AccordFilm-coated tablet500 mgOral useAccord Healthcare Ltd  2011-10-03Not applicableEu
Levetiracetam AccordFilm-coated tablet1000 mgOral useAccord Healthcare Ltd  2011-10-03Not applicableEu
Levetiracetam AccordFilm-coated tablet1000 mgOral useAccord Healthcare Ltd  2011-10-03Not applicableEu
Levetiracetam AccordFilm-coated tablet1000 mgOral useAccord Healthcare Ltd  2011-10-03Not applicableEu
Levetiracetam AccordFilm-coated tablet500 mgOral useAccord Healthcare Ltd  2011-10-03Not applicableEu
Levetiracetam ActavisFilm-coated tablet250 mgOral useActavis Group Ptc Ehf 2011-10-03Not applicableEu
Levetiracetam ActavisFilm-coated tablet750 mgOral useActavis Group Ptc Ehf 2011-10-03Not applicableEu
Levetiracetam ActavisFilm-coated tablet1000 mgOral useActavis Group Ptc Ehf 2011-10-03Not applicableEu
Levetiracetam ActavisFilm-coated tablet500 mgOral useActavis Group Ptc Ehf 2011-10-03Not applicableEu
Levetiracetam ActavisFilm-coated tablet750 mgOral useActavis Group Ptc Ehf 2011-10-03Not applicableEu
Levetiracetam ActavisFilm-coated tablet500 mgOral useActavis Group Ptc Ehf 2011-10-03Not applicableEu
Levetiracetam ActavisFilm-coated tablet750 mgOral useActavis Group Ptc Ehf 2011-10-03Not applicableEu
Levetiracetam ActavisFilm-coated tablet250 mgOral useActavis Group Ptc Ehf 2011-10-03Not applicableEu
Levetiracetam ActavisFilm-coated tablet250 mgOral useActavis Group Ptc Ehf 2011-10-03Not applicableEu
Levetiracetam ActavisFilm-coated tablet500 mgOral useActavis Group Ptc Ehf 2011-10-03Not applicableEu
Levetiracetam ActavisFilm-coated tablet1000 mgOral useActavis Group Ptc Ehf 2011-10-03Not applicableEu
Levetiracetam ActavisFilm-coated tablet250 mgOral useActavis Group Ptc Ehf 2011-10-03Not applicableEu
Levetiracetam ActavisFilm-coated tablet750 mgOral useActavis Group Ptc Ehf 2011-10-03Not applicableEu
Levetiracetam ActavisFilm-coated tablet1000 mgOral useActavis Group Ptc Ehf 2011-10-03Not applicableEu
Levetiracetam ActavisFilm-coated tablet250 mgOral useActavis Group Ptc Ehf 2011-10-03Not applicableEu
Levetiracetam ActavisFilm-coated tablet500 mgOral useActavis Group Ptc Ehf 2011-10-03Not applicableEu
Levetiracetam ActavisFilm-coated tablet1000 mgOral useActavis Group Ptc Ehf 2011-10-03Not applicableEu
Levetiracetam ActavisFilm-coated tablet500 mgOral useActavis Group Ptc Ehf 2011-10-03Not applicableEu
Levetiracetam ActavisFilm-coated tablet500 mgOral useActavis Group Ptc Ehf 2011-10-03Not applicableEu
Levetiracetam ActavisFilm-coated tablet750 mgOral useActavis Group Ptc Ehf 2011-10-03Not applicableEu
Levetiracetam ActavisFilm-coated tablet500 mgOral useActavis Group Ptc Ehf 2011-10-03Not applicableEu
Levetiracetam ActavisFilm-coated tablet1000 mgOral useActavis Group Ptc Ehf 2011-10-03Not applicableEu
Levetiracetam ActavisFilm-coated tablet250 mgOral useActavis Group Ptc Ehf 2011-10-03Not applicableEu
Levetiracetam ActavisFilm-coated tablet250 mgOral useActavis Group Ptc Ehf 2011-10-03Not applicableEu
Levetiracetam ActavisFilm-coated tablet750 mgOral useActavis Group Ptc Ehf 2011-10-03Not applicableEu
Levetiracetam ActavisFilm-coated tablet1000 mgOral useActavis Group Ptc Ehf 2011-10-03Not applicableEu
Levetiracetam ActavisFilm-coated tablet250 mgOral useActavis Group Ptc Ehf 2011-10-03Not applicableEu
Levetiracetam ActavisFilm-coated tablet500 mgOral useActavis Group Ptc Ehf 2011-10-03Not applicableEu
Levetiracetam ActavisFilm-coated tablet1000 mgOral useActavis Group Ptc Ehf 2011-10-03Not applicableEu
Levetiracetam ActavisFilm-coated tablet500 mgOral useActavis Group Ptc Ehf 2011-10-03Not applicableEu
Levetiracetam ActavisFilm-coated tablet750 mgOral useActavis Group Ptc Ehf 2011-10-03Not applicableEu
Levetiracetam ActavisFilm-coated tablet1000 mgOral useActavis Group Ptc Ehf 2011-10-03Not applicableEu
Levetiracetam ActavisFilm-coated tablet250 mgOral useActavis Group Ptc Ehf 2011-10-03Not applicableEu
Levetiracetam ActavisFilm-coated tablet750 mgOral useActavis Group Ptc Ehf 2011-10-03Not applicableEu
Levetiracetam ActavisFilm-coated tablet1000 mgOral useActavis Group Ptc Ehf 2011-10-03Not applicableEu
Levetiracetam ActavisFilm-coated tablet250 mgOral useActavis Group Ptc Ehf 2011-10-03Not applicableEu
Levetiracetam ActavisFilm-coated tablet750 mgOral useActavis Group Ptc Ehf 2011-10-03Not applicableEu
Levetiracetam ActavisFilm-coated tablet1000 mgOral useActavis Group Ptc Ehf 2011-10-03Not applicableEu
Levetiracetam ActavisFilm-coated tablet250 mgOral useActavis Group Ptc Ehf 2011-10-03Not applicableEu
Levetiracetam ActavisFilm-coated tablet500 mgOral useActavis Group Ptc Ehf 2011-10-03Not applicableEu
Levetiracetam ActavisFilm-coated tablet1000 mgOral useActavis Group Ptc Ehf 2011-10-03Not applicableEu
Levetiracetam ActavisFilm-coated tablet500 mgOral useActavis Group Ptc Ehf 2011-10-03Not applicableEu
Levetiracetam ActavisFilm-coated tablet750 mgOral useActavis Group Ptc Ehf 2011-10-03Not applicableEu
Levetiracetam Actavis GroupOral solution100 mg/mlOral useActavis Group Ptc Ehf2011-12-05Not applicableEu
Levetiracetam Actavis GroupOral solution100 mg/mlOral useActavis Group Ptc Ehf2011-12-05Not applicableEu
Levetiracetam Actavis GroupOral solution100 mg/mlOral useActavis Group Ptc Ehf2011-12-05Not applicableEu
Levetiracetam Extended-releasetablet, extended release500 mg/1oralGolden State Medical Supply, Inc.2011-09-12Not applicableUs
Levetiracetam Extended-releasetablet, film coated, extended release750 mg/1oralAnchen Pharmaceuticals, Inc.2011-10-04Not applicableUs
Levetiracetam Extended-releasetablet, extended release750 mg/1oralGolden State Medical Supply, Inc.2011-09-12Not applicableUs
Levetiracetam Extended-releasetablet, film coated, extended release500 mg/1oralAnchen Pharmaceuticals, Inc.2011-10-04Not applicableUs
Levetiracetam HospiraConcentrate for solution for100 mg/ml infusionIntravenous useHospira Uk Limited2014-01-08Not applicableEu
Levetiracetam Hospira InfusionConcentrate for solution for100 mg/mlIntravenous useHospira Uk Limited2014-01-08Not applicableEu
Levetiracetam Levetiracetamsolution100 mg/mLoralCamber Pharmaceuticals, Inc.2015-06-11Not applicableUs
Levetiracetam SunConcentrate for solution for infusion100 mg/mlIntravenous useSun Pharmaceutical Industries Europe B.V.2011-12-14Not applicableEu
Levetiracetam TevaFilm-coated tablet250 mgOral useTeva B.V.2011-08-26Not applicableEu
Levetiracetam TevaFilm-coated tablet750 mgOral useTeva B.V.2011-08-26Not applicableEu
Levetiracetam TevaFilm-coated tablet500 mgOral useTeva B.V.2011-08-26Not applicableEu
Levetiracetam TevaFilm-coated tablet1000 mgOral useTeva B.V.2011-08-26Not applicableEu
Levetiracetam TevaFilm-coated tablet1000 mgOral useTeva B.V.2011-08-26Not applicableEu
Levetiracetam TevaFilm-coated tablet250 mgOral useTeva B.V.2011-08-26Not applicableEu
Levetiracetam TevaFilm-coated tablet750 mgOral useTeva B.V.2011-08-26Not applicableEu
Levetiracetam TevaFilm-coated tablet500 mgOral useTeva B.V.2011-08-26Not applicableEu
Levetiracetam TevaFilm-coated tablet250 mgOral useTeva B.V.2011-08-26Not applicableEu
Levetiracetam TevaFilm-coated tablet750 mgOral useTeva B.V.2011-08-26Not applicableEu
Levetiracetam TevaFilm-coated tablet500 mgOral useTeva B.V.2011-08-26Not applicableEu
Levetiracetam TevaFilm-coated tablet1000 mgOral useTeva B.V.2011-08-26Not applicableEu
Levetiracetam TevaFilm-coated tablet500 mgOral useTeva B.V.2011-08-26Not applicableEu
Levetiracetam TevaFilm-coated tablet1000 mgOral useTeva B.V.2011-08-26Not applicableEu
Levetiracetam TevaFilm-coated tablet250 mgOral useTeva B.V.2011-08-26Not applicableEu
Levetiracetam TevaFilm-coated tablet750 mgOral useTeva B.V.2011-08-26Not applicableEu
Levetiracetam TevaFilm-coated tablet750 mgOral useTeva B.V.2011-08-26Not applicableEu
Levetiracetam TevaFilm-coated tablet250 mgOral useTeva B.V.2011-08-26Not applicableEu
Levetiracetam TevaFilm-coated tablet750 mgOral useTeva B.V.2011-08-26Not applicableEu
Levetiracetam TevaFilm-coated tablet500 mgOral useTeva B.V.2011-08-26Not applicableEu
Levetiracetam TevaFilm-coated tablet1000 mgOral useTeva B.V.2011-08-26Not applicableEu
Levetiracetam TevaFilm-coated tablet500 mgOral useTeva B.V.2011-08-26Not applicableEu
Levetiracetam TevaFilm-coated tablet1000 mgOral useTeva B.V.2011-08-26Not applicableEu
Levetiracetam TevaFilm-coated tablet250 mgOral useTeva B.V.2011-08-26Not applicableEu
Levetiracetam TevaFilm-coated tablet750 mgOral useTeva B.V.2011-08-26Not applicableEu
Levetiracetam TevaFilm-coated tablet1000 mgOral useTeva B.V.2011-08-26Not applicableEu
Levetiracetam TevaFilm-coated tablet250 mgOral useTeva B.V.2011-08-26Not applicableEu
Levetiracetam TevaFilm-coated tablet750 mgOral useTeva B.V.2011-08-26Not applicableEu
Levetiracetam TevaFilm-coated tablet250 mgOral useTeva B.V.2011-08-26Not applicableEu
Levetiracetam TevaFilm-coated tablet500 mgOral useTeva B.V.2011-08-26Not applicableEu
Levetiracetam TevaFilm-coated tablet500 mgOral useTeva B.V.2011-08-26Not applicableEu
Levetiracetam TevaFilm-coated tablet1000 mgOral useTeva B.V.2011-08-26Not applicableEu
Levetiractamtablet250 mg/1oralREMEDYREPACK INC.2011-11-07Not applicableUs
Roweepratablet, film coated500 mg/1oralOwp Pharmaceuticals, Inc.2016-01-11Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII44YRR34555
CAS number102767-28-2
WeightAverage: 170.212
Monoisotopic: 170.105527699
Chemical FormulaC8H14N2O2
InChI KeyHPHUVLMMVZITSG-LURJTMIESA-N
InChI
InChI=1S/C8H14N2O2/c1-2-6(8(9)12)10-5-3-4-7(10)11/h6H,2-5H2,1H3,(H2,9,12)/t6-/m0/s1
IUPAC Name
(2S)-2-(2-oxopyrrolidin-1-yl)butanamide
SMILES
CC[[email protected]](N1CCCC1=O)C(N)=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as alpha amino acids and derivatives. These are amino acids in which the amino group is attached to the carbon atom immediately adjacent to the carboxylate group (alpha carbon), or a derivative thereof.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentAlpha amino acids and derivatives
Alternative Parents
Substituents
  • Alpha-amino acid or derivatives
  • Fatty amide
  • Pyrrolidone
  • 2-pyrrolidone
  • N-alkylpyrrolidine
  • Fatty acyl
  • Tertiary carboxylic acid amide
  • Pyrrolidine
  • Carboxamide group
  • Primary carboxylic acid amide
  • Lactam
  • Organoheterocyclic compound
  • Azacycle
  • Carbonyl group
  • Organic nitrogen compound
  • Organooxygen compound
  • Organonitrogen compound
  • Hydrocarbon derivative
  • Organic oxide
  • Organic oxygen compound
  • Aliphatic heteromonocyclic compound
Molecular FrameworkAliphatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationUsed as adjunctive therapy in the treatment of partial onset seizures in adults and children 4 years of age and older with epilepsy.
PharmacodynamicsNot Available
Mechanism of actionThe precise mechanism(s) by which levetiracetam exerts its antiepileptic effect is unknown. The antiepileptic activity of levetiracetam was assessed in a number of animal models of epileptic seizures. Levetiracetam did not inhibit single seizures induced by maximal stimulation with electrical current or different chemoconvulsants and showed only minimal activity in submaximal stimulation and in threshold tests. Protection was observed, however, against secondarily generalized activity from focal seizures induced by pilocarpine and kainic acid, two chemoconvulsants that induce seizures that mimic some features of human complex partial seizures with secondary generalization. Levetiracetam also displayed inhibitory properties in the kindling model in rats, another model of human complex partial seizures, both during kindling development and in the fully kindled state. The predictive value of these animal models for specific types of human epilepsy is uncertain. Levetiracetam is thought to stimulate synaptic vesicle protein 2A (SV2A), inhibiting neurotransmitter release.
Related Articles
AbsorptionRapidly and almost completely absorbed after oral administration (99%). Peak plasma concentrations occurring in about an hour following oral administration in fasted subjects.
Volume of distributionNot Available
Protein bindingVery low (<10%)
Metabolism

The major metabolic pathway of levetiracetam (24% of dose) is an enzymatic hydrolysis of the acetamide group. No CYP450 metabolism detected.

Route of eliminationSixty-six percent (66%) of the dose is renally excreted unchanged. The metabolites have no known pharmacological activity and are renally excreted. The mechanism of excretion is glomerular filtration with subsequent partial tubular reabsorption.
Half life6-8 hours
Clearance
  • 0.96 mL/min/kg
ToxicitySide effects include aggression, agitation, coma, drowsiness, reduced consciousness, slowed breathing
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.988
Blood Brain Barrier+0.9821
Caco-2 permeable-0.6114
P-glycoprotein substrateSubstrate0.5137
P-glycoprotein inhibitor INon-inhibitor0.5612
P-glycoprotein inhibitor IINon-inhibitor0.8786
Renal organic cation transporterNon-inhibitor0.7024
CYP450 2C9 substrateNon-substrate0.8801
CYP450 2D6 substrateNon-substrate0.8184
CYP450 3A4 substrateNon-substrate0.5191
CYP450 1A2 substrateNon-inhibitor0.9394
CYP450 2C9 inhibitorNon-inhibitor0.7603
CYP450 2D6 inhibitorNon-inhibitor0.9471
CYP450 2C19 inhibitorNon-inhibitor0.8459
CYP450 3A4 inhibitorNon-inhibitor0.9669
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9502
Ames testNon AMES toxic0.8783
CarcinogenicityNon-carcinogens0.9094
BiodegradationNot ready biodegradable0.9305
Rat acute toxicity2.1707 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9206
hERG inhibition (predictor II)Non-inhibitor0.8735
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Tablet, extended releaseoral1000 mg/1
Tablet, extended releaseoral1500 mg/1
Tabletoral250 mg
Tabletoral500 mg
Tabletoral750 mg
Injectionintravenous10 mg/mL
Injectionintravenous100 mg/mL
Injectionintravenous15 mg/mL
Injectionintravenous5 mg/mL
Injection, solutionintravenous100 mg/mL
Injection, solutionintravenous500 mg/5mL
Injection, solution, concentrateintravenous100 mg/mL
Injection, solution, concentrateintravenous500 mg/5mL
Solutionoral100 mg/mL
Solutionoral100 mg/5mL
Tabletoral1000 mg/1
Tabletoral250 mg/1
Tabletoral500 mg/1
Tabletoral750 mg/1
Tablet, extended releaseoral500 mg/1
Tablet, extended releaseoral750 mg/1
Tablet, film coatedoral1000 mg/1
Tablet, film coatedoral250 mg/1
Tablet, film coatedoral500 mg/1
Tablet, film coatedoral750 mg/1
Tablet, film coated, extended releaseoral1000 mg/1
Tablet, film coated, extended releaseoral500 mg/1
Tablet, film coated, extended releaseoral750 mg/1
Film-coated tabletOral use1000 mg
Film-coated tabletOral use250 mg
Film-coated tabletOral use500 mg
Film-coated tabletOral use750 mg
Film-coated tablet page 1 of 2Oral use500 mg
Film-coated tablet page 2 of 2Oral use1000 mg
Oral solutionOral use100 mg/ml
Concentrate for solution forIntravenous use100 mg/ml infusion
Concentrate for solution forIntravenous use100 mg/ml
Concentrate for solution for infusionIntravenous use100 mg/ml
Tablet, for suspensionoral1000 mg/1
Tablet, for suspensionoral250 mg/1
Tablet, for suspensionoral500 mg/1
Tablet, for suspensionoral750 mg/1
Prices
Unit descriptionCostUnit
Keppra 500 mg/5 ml vial9.28USD ml
Keppra 1000 mg tablet9.01USD tablet
Levetiracetam 1000 mg tablet7.18USD tablet
Keppra xr 750 mg tablet6.46USD tablet
Keppra xr 500 mg tablet6.43USD tablet
Keppra 500 mg tablet5.09USD tablet
Levetiracetam 750 mg tablet4.86USD tablet
Keppra 750 mg tablet4.74USD tablet
Keppra XR 500 mg 24 Hour tablet4.47USD tablet
Keppra 250 mg tablet3.62USD tablet
Levetiracetam 500 mg tablet3.59USD tablet
Levetiracetam 250 mg tablet2.93USD tablet
Apo-Levetiracetam 750 mg Tablet1.7USD tablet
Co Levetiracetam 750 mg Tablet1.7USD tablet
Pms-Levetiracetam 750 mg Tablet1.7USD tablet
Apo-Levetiracetam 500 mg Tablet1.23USD tablet
Co Levetiracetam 500 mg Tablet1.23USD tablet
Pms-Levetiracetam 500 mg Tablet1.23USD tablet
Apo-Levetiracetam 250 mg Tablet1.01USD tablet
Co Levetiracetam 250 mg Tablet1.01USD tablet
Pms-Levetiracetam 250 mg Tablet1.01USD tablet
Keppra 100 mg/ml Solution0.95USD ml
Levetiracetam 100 mg/ml Solution0.68USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6471992 No1998-02-202018-02-20Us
US7858122 No2008-09-172028-09-17Us
US8802142 Yes2011-12-072031-12-07Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP-0.6Not Available
Predicted Properties
PropertyValueSource
Water Solubility298.0 mg/mLALOGPS
logP-0.64ALOGPS
logP-0.59ChemAxon
logS0.24ALOGPS
pKa (Strongest Acidic)16.09ChemAxon
pKa (Strongest Basic)-1.6ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area63.4 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity44.08 m3·mol-1ChemAxon
Polarizability17.79 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Tooru Futagawa, Jean-Pierre Canvat, Emile Cavoy, Michel Deleers, Michel Hamende, Vincent Zimmermann, “Process for the preparation of levetiracetam.” U.S. Patent US6107492, issued September, 1996.

US6107492
General ReferencesNot Available
External Links
ATC CodesN03AX14
AHFS Codes
  • 28:12.92
PDB EntriesNot Available
FDA labelDownload (52.5 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Levetiracetam.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Levetiracetam.
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Levetiracetam.
AcetaminophenThe serum concentration of Levetiracetam can be increased when it is combined with Acetaminophen.
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Levetiracetam.
AfatinibThe serum concentration of Levetiracetam can be increased when it is combined with Afatinib.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Levetiracetam.
AlbendazoleThe serum concentration of Levetiracetam can be increased when it is combined with Albendazole.
AldosteroneThe serum concentration of Levetiracetam can be decreased when it is combined with Aldosterone.
AlectinibThe serum concentration of Levetiracetam can be increased when it is combined with Alectinib.
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Levetiracetam.
AlfentanilThe serum concentration of Levetiracetam can be increased when it is combined with Alfentanil.
AlfentanilThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Alfentanil.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Levetiracetam.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Levetiracetam.
AmantadineThe serum concentration of Levetiracetam can be increased when it is combined with Amantadine.
Aminohippuric acidThe serum concentration of Levetiracetam can be increased when it is combined with Aminohippuric acid.
AmiodaroneThe serum concentration of Levetiracetam can be decreased when it is combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Levetiracetam.
AmitriptylineThe serum concentration of Levetiracetam can be increased when it is combined with Amitriptyline.
AmitriptylineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Amitriptyline.
AmlodipineThe serum concentration of Levetiracetam can be increased when it is combined with Amlodipine.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Levetiracetam.
AmoxapineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Levetiracetam.
AmprenavirThe serum concentration of Levetiracetam can be decreased when it is combined with Amprenavir.
AmsacrineThe serum concentration of Levetiracetam can be increased when it is combined with Amsacrine.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Levetiracetam.
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Levetiracetam.
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Levetiracetam.
AstemizoleThe serum concentration of Levetiracetam can be increased when it is combined with Astemizole.
AtazanavirThe serum concentration of Levetiracetam can be increased when it is combined with Atazanavir.
AtenololThe serum concentration of Levetiracetam can be increased when it is combined with Atenolol.
AtorvastatinThe serum concentration of Levetiracetam can be increased when it is combined with Atorvastatin.
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Levetiracetam.
AzelastineLevetiracetam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe serum concentration of Levetiracetam can be increased when it is combined with Azelastine.
AzithromycinThe serum concentration of Levetiracetam can be increased when it is combined with Azithromycin.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Levetiracetam.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Levetiracetam.
BenzocaineThe serum concentration of Levetiracetam can be increased when it is combined with Benzocaine.
BenzocaineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Benzocaine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Levetiracetam.
BepridilThe serum concentration of Levetiracetam can be increased when it is combined with Bepridil.
BiperidenThe serum concentration of Levetiracetam can be increased when it is combined with Biperiden.
BosutinibThe serum concentration of Levetiracetam can be increased when it is combined with Bosutinib.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Levetiracetam.
BrimonidineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Levetiracetam.
BromocriptineThe serum concentration of Levetiracetam can be increased when it is combined with Bromocriptine.
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Levetiracetam.
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Levetiracetam.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Levetiracetam.
BuprenorphineThe serum concentration of Levetiracetam can be increased when it is combined with Buprenorphine.
BuprenorphineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Buprenorphine.
BuspironeThe serum concentration of Levetiracetam can be increased when it is combined with Buspirone.
BuspironeThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Buspirone.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Levetiracetam.
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Levetiracetam.
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Levetiracetam.
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Levetiracetam.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Levetiracetam.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Levetiracetam.
CabazitaxelThe serum concentration of Levetiracetam can be increased when it is combined with Cabazitaxel.
CaffeineThe serum concentration of Levetiracetam can be increased when it is combined with Caffeine.
CanagliflozinThe serum concentration of Levetiracetam can be increased when it is combined with Canagliflozin.
CandesartanThe serum concentration of Levetiracetam can be increased when it is combined with Candesartan.
CaptoprilThe serum concentration of Levetiracetam can be increased when it is combined with Captopril.
CarbamazepineThe serum concentration of Levetiracetam can be decreased when it is combined with Carbamazepine.
CarbamazepineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Carbamazepine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Levetiracetam.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Levetiracetam.
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Levetiracetam.
CarvedilolThe serum concentration of Levetiracetam can be increased when it is combined with Carvedilol.
CaspofunginThe serum concentration of Levetiracetam can be increased when it is combined with Caspofungin.
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Levetiracetam.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Levetiracetam.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Levetiracetam.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Levetiracetam.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Levetiracetam.
ChloroquineThe serum concentration of Levetiracetam can be increased when it is combined with Chloroquine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Levetiracetam.
ChlorpromazineThe serum concentration of Levetiracetam can be increased when it is combined with Chlorpromazine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Chlorpromazine.
ChlorpropamideThe serum concentration of Levetiracetam can be increased when it is combined with Chlorpropamide.
ChlorprothixeneThe serum concentration of Levetiracetam can be increased when it is combined with Chlorprothixene.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Chlorprothixene.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Levetiracetam.
CholesterolThe serum concentration of Levetiracetam can be increased when it is combined with Cholesterol.
Cholic AcidThe serum concentration of Levetiracetam can be decreased when it is combined with Cholic Acid.
CilazaprilThe serum concentration of Levetiracetam can be increased when it is combined with Cilazapril.
CimetidineThe serum concentration of Levetiracetam can be decreased when it is combined with Cimetidine.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Levetiracetam.
CiprofloxacinThe serum concentration of Levetiracetam can be increased when it is combined with Ciprofloxacin.
CitalopramThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Citalopram.
CitalopramThe serum concentration of Levetiracetam can be increased when it is combined with Citalopram.
ClarithromycinThe serum concentration of Levetiracetam can be increased when it is combined with Clarithromycin.
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Levetiracetam.
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Levetiracetam.
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Levetiracetam.
ClofazimineThe serum concentration of Levetiracetam can be increased when it is combined with Clofazimine.
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Levetiracetam.
ClomipramineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Clomipramine.
ClomipramineThe serum concentration of Levetiracetam can be increased when it is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Levetiracetam.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Levetiracetam.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Levetiracetam.
ClotrimazoleThe serum concentration of Levetiracetam can be decreased when it is combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Levetiracetam.
CobicistatThe serum concentration of Levetiracetam can be increased when it is combined with Cobicistat.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Levetiracetam.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Levetiracetam.
ColchicineThe serum concentration of Levetiracetam can be increased when it is combined with Colchicine.
ColforsinThe serum concentration of Levetiracetam can be increased when it is combined with Colforsin.
CrizotinibThe serum concentration of Levetiracetam can be increased when it is combined with Crizotinib.
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Levetiracetam.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Levetiracetam.
CyclophosphamideThe serum concentration of Levetiracetam can be increased when it is combined with Cyclophosphamide.
CyclosporineThe serum concentration of Levetiracetam can be decreased when it is combined with Cyclosporine.
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Levetiracetam.
DaclatasvirThe serum concentration of Levetiracetam can be increased when it is combined with Daclatasvir.
DactinomycinThe serum concentration of Levetiracetam can be increased when it is combined with Dactinomycin.
DantroleneThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Levetiracetam.
DapoxetineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Dapoxetine.
DasatinibThe serum concentration of Levetiracetam can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Levetiracetam can be decreased when it is combined with Daunorubicin.
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Levetiracetam.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Levetiracetam.
DesipramineThe serum concentration of Levetiracetam can be increased when it is combined with Desipramine.
DesipramineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Desipramine.
DesloratadineThe serum concentration of Levetiracetam can be increased when it is combined with Desloratadine.
DesloratadineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Desloratadine.
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Levetiracetam.
DexamethasoneThe serum concentration of Levetiracetam can be decreased when it is combined with Dexamethasone.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Levetiracetam.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Levetiracetam.
DextromethorphanThe serum concentration of Levetiracetam can be increased when it is combined with Dextromethorphan.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Levetiracetam.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Levetiracetam.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Levetiracetam.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Levetiracetam.
DiclofenacThe serum concentration of Levetiracetam can be increased when it is combined with Diclofenac.
DifenoxinThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Difenoxin.
DigoxinThe serum concentration of Levetiracetam can be decreased when it is combined with Digoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Levetiracetam.
DihydroergotamineThe serum concentration of Levetiracetam can be increased when it is combined with Dihydroergotamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Levetiracetam.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Levetiracetam.
DiltiazemThe serum concentration of Levetiracetam can be increased when it is combined with Diltiazem.
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Levetiracetam.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Levetiracetam.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Levetiracetam.
DipyridamoleThe serum concentration of Levetiracetam can be increased when it is combined with Dipyridamole.
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Levetiracetam.
DoxazosinThe serum concentration of Levetiracetam can be increased when it is combined with Doxazosin.
DoxepinThe serum concentration of Levetiracetam can be increased when it is combined with Doxepin.
DoxepinThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Doxepin.
DoxorubicinThe serum concentration of Levetiracetam can be decreased when it is combined with Doxorubicin.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Levetiracetam.
DoxylamineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Levetiracetam.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Levetiracetam.
DronedaroneThe serum concentration of Levetiracetam can be increased when it is combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Levetiracetam.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Levetiracetam.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Levetiracetam.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Levetiracetam.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Levetiracetam.
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Levetiracetam.
ElbasvirThe serum concentration of Levetiracetam can be increased when it is combined with Elbasvir.
EnalaprilThe serum concentration of Levetiracetam can be increased when it is combined with Enalapril.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Levetiracetam.
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Levetiracetam.
EnzalutamideThe serum concentration of Levetiracetam can be increased when it is combined with Enzalutamide.
ErgonovineThe serum concentration of Levetiracetam can be increased when it is combined with Ergonovine.
ErgotamineThe serum concentration of Levetiracetam can be increased when it is combined with Ergotamine.
ErythromycinThe serum concentration of Levetiracetam can be decreased when it is combined with Erythromycin.
EscitalopramThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Escitalopram.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Levetiracetam.
EstramustineThe serum concentration of Levetiracetam can be increased when it is combined with Estramustine.
EstriolThe serum concentration of Levetiracetam can be decreased when it is combined with Estriol.
EstroneThe serum concentration of Levetiracetam can be decreased when it is combined with Estrone.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Levetiracetam.
EthanolLevetiracetam may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Levetiracetam.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Levetiracetam.
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Levetiracetam.
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Levetiracetam.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Levetiracetam.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Levetiracetam.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Levetiracetam.
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Levetiracetam.
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Levetiracetam.
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Levetiracetam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Levetiracetam.
EtoperidoneThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Etoperidone.
EtoposideThe serum concentration of Levetiracetam can be increased when it is combined with Etoposide.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Levetiracetam.
EtravirineThe serum concentration of Levetiracetam can be increased when it is combined with Etravirine.
EzogabineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Levetiracetam.
FelodipineThe serum concentration of Levetiracetam can be increased when it is combined with Felodipine.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Levetiracetam.
FenfluramineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Fenfluramine.
FentanylThe serum concentration of Levetiracetam can be increased when it is combined with Fentanyl.
FentanylThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Fentanyl.
FexofenadineThe serum concentration of Levetiracetam can be increased when it is combined with Fexofenadine.
FexofenadineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Fexofenadine.
FidaxomicinThe serum concentration of Levetiracetam can be increased when it is combined with Fidaxomicin.
FlibanserinThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Flibanserin.
FluconazoleThe serum concentration of Levetiracetam can be increased when it is combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Levetiracetam.
FlunarizineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Levetiracetam.
FluoxetineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Fluoxetine.
FluoxetineThe serum concentration of Levetiracetam can be increased when it is combined with Fluoxetine.
FlupentixolThe serum concentration of Levetiracetam can be increased when it is combined with Flupentixol.
FlupentixolThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Flupentixol.
FluphenazineThe serum concentration of Levetiracetam can be increased when it is combined with Fluphenazine.
FluphenazineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Fluphenazine.
FlurazepamThe serum concentration of Levetiracetam can be increased when it is combined with Flurazepam.
FlurazepamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Flurazepam.
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Levetiracetam.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Levetiracetam.
FluvoxamineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Fluvoxamine.
FluvoxamineThe serum concentration of Levetiracetam can be increased when it is combined with Fluvoxamine.
FosphenytoinThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Levetiracetam.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Levetiracetam.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Levetiracetam is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Levetiracetam.
GefitinibThe serum concentration of Levetiracetam can be increased when it is combined with Gefitinib.
GenisteinThe serum concentration of Levetiracetam can be increased when it is combined with Genistein.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Levetiracetam.
GlyburideThe serum concentration of Levetiracetam can be increased when it is combined with Glyburide.
GlycerolThe serum concentration of Levetiracetam can be increased when it is combined with Glycerol.
Gramicidin DThe serum concentration of Levetiracetam can be increased when it is combined with Gramicidin D.
GrepafloxacinThe serum concentration of Levetiracetam can be increased when it is combined with Grepafloxacin.
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Levetiracetam.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Levetiracetam.
HaloperidolThe serum concentration of Levetiracetam can be increased when it is combined with Haloperidol.
HaloperidolThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Haloperidol.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Levetiracetam.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Levetiracetam.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Levetiracetam.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Levetiracetam.
HydrocortisoneThe serum concentration of Levetiracetam can be increased when it is combined with Hydrocortisone.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Levetiracetam.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Levetiracetam.
HydroxyzineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Hydroxyzine.
IdelalisibThe serum concentration of Levetiracetam can be increased when it is combined with Idelalisib.
IloperidoneThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Iloperidone.
ImatinibThe serum concentration of Levetiracetam can be increased when it is combined with Imatinib.
ImipramineThe serum concentration of Levetiracetam can be increased when it is combined with Imipramine.
ImipramineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Imipramine.
IndalpineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Indalpine.
IndinavirThe serum concentration of Levetiracetam can be decreased when it is combined with Indinavir.
IndomethacinThe serum concentration of Levetiracetam can be increased when it is combined with Indomethacin.
IsavuconazoniumThe serum concentration of Levetiracetam can be increased when it is combined with Isavuconazonium.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Levetiracetam.
ItraconazoleThe serum concentration of Levetiracetam can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Levetiracetam can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Levetiracetam can be increased when it is combined with Ivermectin.
KetamineThe serum concentration of Levetiracetam can be increased when it is combined with Ketamine.
KetamineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Ketamine.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Levetiracetam.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Levetiracetam.
KetoconazoleThe serum concentration of Levetiracetam can be increased when it is combined with Ketoconazole.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Levetiracetam.
LansoprazoleThe serum concentration of Levetiracetam can be increased when it is combined with Lansoprazole.
LapatinibThe serum concentration of Levetiracetam can be increased when it is combined with Lapatinib.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Levetiracetam.
LevocabastineThe risk or severity of adverse effects can be increased when Levocabastine is combined with Levetiracetam.
LevocetirizineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Levodopa.
LevofloxacinThe serum concentration of Levetiracetam can be increased when it is combined with Levofloxacin.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Levetiracetam.
LevomilnacipranThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Levetiracetam.
LevothyroxineThe serum concentration of Levetiracetam can be decreased when it is combined with Levothyroxine.
LidocaineThe serum concentration of Levetiracetam can be increased when it is combined with Lidocaine.
LidocaineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Lidocaine.
LiothyronineThe serum concentration of Levetiracetam can be decreased when it is combined with Liothyronine.
LiotrixThe serum concentration of Levetiracetam can be decreased when it is combined with Liotrix.
LisinoprilThe serum concentration of Levetiracetam can be increased when it is combined with Lisinopril.
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Levetiracetam.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Levetiracetam.
LomitapideThe serum concentration of Levetiracetam can be increased when it is combined with Lomitapide.
LoperamideThe serum concentration of Levetiracetam can be increased when it is combined with Loperamide.
LopinavirThe serum concentration of Levetiracetam can be increased when it is combined with Lopinavir.
LoratadineThe serum concentration of Levetiracetam can be increased when it is combined with Loratadine.
LoratadineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Levetiracetam.
LosartanThe serum concentration of Levetiracetam can be increased when it is combined with Losartan.
LovastatinThe serum concentration of Levetiracetam can be increased when it is combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Levetiracetam.
Lu AA21004The risk or severity of adverse effects can be increased when Levetiracetam is combined with Lu AA21004.
LumacaftorThe serum concentration of Levetiracetam can be decreased when it is combined with Lumacaftor.
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Levetiracetam.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Levetiracetam.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Magnesium Sulfate.
MaprotilineThe serum concentration of Levetiracetam can be increased when it is combined with Maprotiline.
MaprotilineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Maprotiline.
MebendazoleThe serum concentration of Levetiracetam can be increased when it is combined with Mebendazole.
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Levetiracetam.
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Levetiracetam.
MefloquineThe serum concentration of Levetiracetam can be increased when it is combined with Mefloquine.
Megestrol acetateThe serum concentration of Levetiracetam can be increased when it is combined with Megestrol acetate.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Levetiracetam.
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Levetiracetam.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Levetiracetam.
MeprobamateThe serum concentration of Levetiracetam can be increased when it is combined with Meprobamate.
MeprobamateThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Meprobamate.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Levetiracetam.
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Levetiracetam.
MethadoneThe serum concentration of Levetiracetam can be increased when it is combined with Methadone.
MethadoneThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Methadone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Levetiracetam.
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Levetiracetam.
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Levetiracetam.
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Levetiracetam.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Levetiracetam.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Levetiracetam.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Levetiracetam.
MethsuximideThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Methsuximide.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Levetiracetam.
MetoprololThe serum concentration of Levetiracetam can be increased when it is combined with Metoprolol.
MetyrosineLevetiracetam may increase the sedative activities of Metyrosine.
MianserinThe therapeutic efficacy of Levetiracetam can be decreased when used in combination with Mianserin.
MibefradilThe serum concentration of Levetiracetam can be increased when it is combined with Mibefradil.
MiconazoleThe serum concentration of Levetiracetam can be increased when it is combined with Miconazole.
MidazolamThe serum concentration of Levetiracetam can be decreased when it is combined with Midazolam.
MidazolamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Midazolam.
MifepristoneThe serum concentration of Levetiracetam can be decreased when it is combined with Mifepristone.
MilnacipranThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Levetiracetam.
MirtazapineLevetiracetam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Levetiracetam.
MitomycinThe serum concentration of Levetiracetam can be increased when it is combined with Mitomycin.
MitoxantroneThe serum concentration of Levetiracetam can be decreased when it is combined with Mitoxantrone.
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Levetiracetam.
MorphineThe serum concentration of Levetiracetam can be increased when it is combined with Morphine.
MorphineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Morphine.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Levetiracetam.
NabiloneThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Nabilone.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Levetiracetam.
NaltrexoneThe serum concentration of Levetiracetam can be increased when it is combined with Naltrexone.
NaringeninThe serum concentration of Levetiracetam can be increased when it is combined with Naringenin.
NefazodoneThe serum concentration of Levetiracetam can be decreased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Levetiracetam can be decreased when it is combined with Nelfinavir.
NeostigmineThe serum concentration of Levetiracetam can be increased when it is combined with Neostigmine.
NicardipineThe serum concentration of Levetiracetam can be increased when it is combined with Nicardipine.
NifedipineThe serum concentration of Levetiracetam can be decreased when it is combined with Nifedipine.
NilotinibThe serum concentration of Levetiracetam can be increased when it is combined with Nilotinib.
NisoldipineThe serum concentration of Levetiracetam can be increased when it is combined with Nisoldipine.
NitrazepamThe serum concentration of Levetiracetam can be increased when it is combined with Nitrazepam.
NitrazepamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Nitrazepam.
NitrendipineThe serum concentration of Levetiracetam can be increased when it is combined with Nitrendipine.
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Levetiracetam.
NorethisteroneThe serum concentration of Levetiracetam can be decreased when it is combined with Norethisterone.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Levetiracetam.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Levetiracetam.
OlanzapineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Olanzapine.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Levetiracetam.
OmeprazoleThe serum concentration of Levetiracetam can be increased when it is combined with Omeprazole.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Levetiracetam.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Levetiracetam.
OrlistatThe serum concentration of Levetiracetam can be decreased when it is combined with Orlistat.
OrphenadrineLevetiracetam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Levetiracetam.
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Levetiracetam.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Levetiracetam.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Levetiracetam.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Levetiracetam.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Levetiracetam.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Levetiracetam.
P-NitrophenolThe serum concentration of Levetiracetam can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe serum concentration of Levetiracetam can be increased when it is combined with Paclitaxel.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Levetiracetam.
Palmitic AcidThe serum concentration of Levetiracetam can be increased when it is combined with Palmitic Acid.
PantoprazoleThe serum concentration of Levetiracetam can be increased when it is combined with Pantoprazole.
ParaldehydeLevetiracetam may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Levetiracetam.
ParoxetineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Paroxetine.
ParoxetineThe serum concentration of Levetiracetam can be increased when it is combined with Paroxetine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Levetiracetam.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Levetiracetam.
PerampanelThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Perampanel.
PerindoprilThe serum concentration of Levetiracetam can be increased when it is combined with Perindopril.
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Levetiracetam.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Levetiracetam.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Levetiracetam.
PhenobarbitalThe serum concentration of Levetiracetam can be decreased when it is combined with Phenobarbital.
PhenobarbitalThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Phenobarbital.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Levetiracetam.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Levetiracetam.
PimozideThe serum concentration of Levetiracetam can be increased when it is combined with Pimozide.
PimozideThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Pimozide.
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Levetiracetam.
PipotiazineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Pizotifen.
Platelet Activating FactorThe serum concentration of Levetiracetam can be decreased when it is combined with Platelet Activating Factor.
PomalidomideThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Pomalidomide.
PonatinibThe serum concentration of Levetiracetam can be increased when it is combined with Ponatinib.
PosaconazoleThe serum concentration of Levetiracetam can be increased when it is combined with Posaconazole.
PramipexoleLevetiracetam may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Levetiracetam.
PravastatinThe serum concentration of Levetiracetam can be increased when it is combined with Pravastatin.
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Levetiracetam.
PrazosinThe serum concentration of Levetiracetam can be increased when it is combined with Prazosin.
PrednisoneThe serum concentration of Levetiracetam can be increased when it is combined with Prednisone.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Levetiracetam.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Levetiracetam.
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Levetiracetam.
ProbenecidThe serum concentration of Levetiracetam can be increased when it is combined with Probenecid.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Levetiracetam.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Levetiracetam.
ProgesteroneThe serum concentration of Levetiracetam can be decreased when it is combined with Progesterone.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Levetiracetam.
PromethazineThe serum concentration of Levetiracetam can be increased when it is combined with Promethazine.
PromethazineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Promethazine.
PropafenoneThe serum concentration of Levetiracetam can be increased when it is combined with Propafenone.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Levetiracetam.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Levetiracetam.
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Levetiracetam.
PropranololThe serum concentration of Levetiracetam can be increased when it is combined with Propranolol.
ProtriptylineThe serum concentration of Levetiracetam can be increased when it is combined with Protriptyline.
ProtriptylineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Protriptyline.
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Levetiracetam.
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Levetiracetam.
QuercetinThe serum concentration of Levetiracetam can be increased when it is combined with Quercetin.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Levetiracetam.
QuinacrineThe serum concentration of Levetiracetam can be increased when it is combined with Quinacrine.
QuinidineThe serum concentration of Levetiracetam can be increased when it is combined with Quinidine.
QuinineThe serum concentration of Levetiracetam can be increased when it is combined with Quinine.
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Levetiracetam.
RanitidineThe serum concentration of Levetiracetam can be increased when it is combined with Ranitidine.
RanolazineThe serum concentration of Levetiracetam can be increased when it is combined with Ranolazine.
ReboxetineThe serum concentration of Levetiracetam can be increased when it is combined with Reboxetine.
RegorafenibThe serum concentration of Levetiracetam can be increased when it is combined with Regorafenib.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Levetiracetam.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Levetiracetam.
ReserpineThe serum concentration of Levetiracetam can be decreased when it is combined with Reserpine.
ReserpineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Reserpine.
RifampicinThe serum concentration of Levetiracetam can be decreased when it is combined with Rifampicin.
RilpivirineThe serum concentration of Levetiracetam can be increased when it is combined with Rilpivirine.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Levetiracetam.
RitonavirThe serum concentration of Levetiracetam can be decreased when it is combined with Ritonavir.
RolapitantThe serum concentration of Levetiracetam can be increased when it is combined with Rolapitant.
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Levetiracetam.
RopiniroleLevetiracetam may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Levetiracetam.
RotigotineLevetiracetam may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Levetiracetam.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Levetiracetam.
SaquinavirThe serum concentration of Levetiracetam can be decreased when it is combined with Saquinavir.
ScopolamineThe serum concentration of Levetiracetam can be increased when it is combined with Scopolamine.
ScopolamineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Levetiracetam.
SelegilineThe serum concentration of Levetiracetam can be increased when it is combined with Selegiline.
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Levetiracetam.
SertralineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Sertraline.
SertralineThe serum concentration of Levetiracetam can be increased when it is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Levetiracetam.
SimeprevirThe serum concentration of Levetiracetam can be increased when it is combined with Simeprevir.
SimvastatinThe serum concentration of Levetiracetam can be increased when it is combined with Simvastatin.
SirolimusThe serum concentration of Levetiracetam can be decreased when it is combined with Sirolimus.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Levetiracetam.
SorafenibThe serum concentration of Levetiracetam can be increased when it is combined with Sorafenib.
SpironolactoneThe serum concentration of Levetiracetam can be increased when it is combined with Spironolactone.
St. John's WortThe serum concentration of Levetiracetam can be decreased when it is combined with St. John&#39;s Wort.
StaurosporineThe serum concentration of Levetiracetam can be increased when it is combined with Staurosporine.
StiripentolThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Stiripentol.
StreptozocinThe serum concentration of Levetiracetam can be decreased when it is combined with Streptozocin.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Levetiracetam.
SulfinpyrazoneThe serum concentration of Levetiracetam can be increased when it is combined with Sulfinpyrazone.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Levetiracetam.
SumatriptanThe serum concentration of Levetiracetam can be increased when it is combined with Sumatriptan.
SunitinibThe serum concentration of Levetiracetam can be increased when it is combined with Sunitinib.
SuvorexantThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Suvorexant.
TacrineThe serum concentration of Levetiracetam can be increased when it is combined with Tacrine.
TacrolimusThe serum concentration of Levetiracetam can be decreased when it is combined with Tacrolimus.
TamoxifenThe serum concentration of Levetiracetam can be decreased when it is combined with Tamoxifen.
TapentadolThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Tasimelteon.
Taurocholic AcidThe serum concentration of Levetiracetam can be increased when it is combined with Taurocholic Acid.
TelmisartanThe serum concentration of Levetiracetam can be increased when it is combined with Telmisartan.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Levetiracetam.
TemsirolimusThe serum concentration of Levetiracetam can be increased when it is combined with Temsirolimus.
TerazosinThe serum concentration of Levetiracetam can be increased when it is combined with Terazosin.
TerfenadineThe serum concentration of Levetiracetam can be increased when it is combined with Terfenadine.
TesmilifeneThe serum concentration of Levetiracetam can be decreased when it is combined with Tesmilifene.
TestosteroneThe serum concentration of Levetiracetam can be increased when it is combined with Testosterone.
TetrabenazineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Levetiracetam.
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Levetiracetam.
ThalidomideLevetiracetam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Levetiracetam.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Levetiracetam.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Levetiracetam.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Levetiracetam.
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Levetiracetam.
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Levetiracetam.
TicagrelorThe serum concentration of Levetiracetam can be increased when it is combined with Ticagrelor.
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Levetiracetam.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Levetiracetam.
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Levetiracetam.
TolvaptanThe serum concentration of Levetiracetam can be increased when it is combined with Tolvaptan.
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Levetiracetam.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Levetiracetam.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Levetiracetam.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Levetiracetam.
TrazodoneThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Trazodone.
TrazodoneThe serum concentration of Levetiracetam can be decreased when it is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Levetiracetam.
TrifluoperazineThe serum concentration of Levetiracetam can be increased when it is combined with Trifluoperazine.
TrifluoperazineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Trifluoperazine.
TriflupromazineThe serum concentration of Levetiracetam can be increased when it is combined with Triflupromazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Triflupromazine.
TrimethoprimThe serum concentration of Levetiracetam can be decreased when it is combined with Trimethoprim.
TrimipramineThe serum concentration of Levetiracetam can be increased when it is combined with Trimipramine.
TrimipramineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Levetiracetam.
TroleandomycinThe serum concentration of Levetiracetam can be increased when it is combined with Troleandomycin.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Levetiracetam.
VenlafaxineThe serum concentration of Levetiracetam can be increased when it is combined with Venlafaxine.
VerapamilThe serum concentration of Levetiracetam can be decreased when it is combined with Verapamil.
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Levetiracetam.
VilazodoneThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Vilazodone.
VinblastineThe serum concentration of Levetiracetam can be decreased when it is combined with Vinblastine.
VincristineThe serum concentration of Levetiracetam can be decreased when it is combined with Vincristine.
VinorelbineThe serum concentration of Levetiracetam can be increased when it is combined with Vinorelbine.
VortioxetineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Levetiracetam.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Levetiracetam.
ZiconotideThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Zimelidine.
ZimelidineThe serum concentration of Levetiracetam can be increased when it is combined with Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Levetiracetam.
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Levetiracetam.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Levetiracetam.
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Levetiracetam.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Levetiracetam.
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Levetiracetam.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Levetiracetam.
Food Interactions
  • Take without regard to meals. Food does not affect bioavailabilty.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Transmembrane transporter activity
Specific Function:
Plays a role in the control of regulated secretion in neural and endocrine cells, enhancing selectively low-frequency neurotransmission. Positively regulates vesicle fusion by maintaining the readily releasable pool of secretory vesicles (By similarity).
Gene Name:
SV2A
Uniprot ID:
Q7L0J3
Molecular Weight:
82694.665 Da
References
  1. Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, Fuks B: The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9861-6. Epub 2004 Jun 21. [PubMed:15210974 ]
  2. Stahl SM: Psychopharmacology of anticonvulsants: levetiracetam as a synaptic vesicle protein modulator. J Clin Psychiatry. 2004 Sep;65(9):1162-3. [PubMed:15367040 ]
  3. Lambeng N, Grossmann M, Chatelain P, Fuks B: Solubilization and immunopurification of rat brain synaptic vesicle protein 2A with maintained binding properties. Neurosci Lett. 2006 May 1;398(1-2):107-12. Epub 2006 Jan 24. [PubMed:16434140 ]
  4. Gillard M, Chatelain P, Fuks B: Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein. Eur J Pharmacol. 2006 Apr 24;536(1-2):102-8. Epub 2006 Mar 10. [PubMed:16556440 ]
  5. Newton HB, Dalton J, Goldlust S, Pearl D: Retrospective analysis of the efficacy and tolerability of levetiracetam in patients with metastatic brain tumors. J Neurooncol. 2007 Sep;84(3):293-6. Epub 2007 Apr 13. [PubMed:17431542 ]
  6. Johannessen Landmark C: Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy. CNS Drugs. 2008;22(1):27-47. [PubMed:18072813 ]
  7. De Smedt T, Raedt R, Vonck K, Boon P: Levetiracetam: the profile of a novel anticonvulsant drug-part I: preclinical data. CNS Drug Rev. 2007 Spring;13(1):43-56. [PubMed:17461889 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1B gives rise to N-type calcium currents. N-type calcium channels belong to the 'high-...
Gene Name:
CACNA1B
Uniprot ID:
Q00975
Molecular Weight:
262493.84 Da
References
  1. De Smedt T, Raedt R, Vonck K, Boon P: Levetiracetam: the profile of a novel anticonvulsant drug-part I: preclinical data. CNS Drug Rev. 2007 Spring;13(1):43-56. [PubMed:17461889 ]
  2. Lukyanetz EA, Shkryl VM, Kostyuk PG: Selective blockade of N-type calcium channels by levetiracetam. Epilepsia. 2002 Jan;43(1):9-18. [PubMed:11879381 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Baltes S, Gastens AM, Fedrowitz M, Potschka H, Kaever V, Loscher W: Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology. 2007 Feb;52(2):333-46. Epub 2006 Oct 10. [PubMed:17045309 ]
  2. Luna-Tortos C, Fedrowitz M, Loscher W: Several major antiepileptic drugs are substrates for human P-glycoprotein. Neuropharmacology. 2008 Dec;55(8):1364-75. doi: 10.1016/j.neuropharm.2008.08.032. Epub 2008 Sep 11. [PubMed:18824002 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Organic anion transmembrane transporter activity
Specific Function:
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name:
ABCC2
Uniprot ID:
Q92887
Molecular Weight:
174205.64 Da
References
  1. Baltes S, Gastens AM, Fedrowitz M, Potschka H, Kaever V, Loscher W: Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology. 2007 Feb;52(2):333-46. Epub 2006 Oct 10. [PubMed:17045309 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 25, 2016 03:31